PointState Capital’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

PointState Capital’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-30,589	Closed	-$5.01M	–	137
2016 Q1	$5.01M	Buy	30,589 +22,222	+266%	+$4.5M	0.14%	56
2015 Q4	$2.74M	Buy	8,367 +2,811	+51%	+$915K	0.07%	76
2015 Q3	$1.79M	Sell	5,556 -5,555	-50%	-$2.44M	0.05%	77
2015 Q2	$4.43M	Sell	11,111 -22,778	-67%	-$9.68M	0.05%	111
2015 Q1	$16.7M	Sell	33,889 -21,778	-39%	-$8.44M	0.23%	70
2014 Q4	$19.9M	Sell	55,667 -69,333	-55%	-$20.6M	0.34%	62
2014 Q3	$24.1M	Buy	125,000 +36,111	+41%	+$7.94M	0.44%	46
2014 Q2	$21.2M	Sell	88,889 -27,222	-23%	-$5.54M	0.27%	58
2014 Q1	$29.7M	Buy	116,111 +24,444	+27%	+$7.47M	0.47%	45
2013 Q4	$18.2M	Sell	91,667 -19,444	-17%	-$3.46M	0.23%	77
2013 Q3	$18.8M	Buy	111,111 +1,667	+2%	+$268K	0.32%	60
2013 Q2	$19.4M	Buy	+109,444	New	+$15.5M	0.33%	64

Other funds holding LUMO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

PointState Capital's LUMO Position: Q2 2016 in Review

PointState Capital sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2016, closing a stake of 30,589 shares — an estimated $5.01M sold.

PointState Capital first reported a position in LUMO in Q2 2013 and held it in 12 quarters. The position peaked at $29.7M in Q1 2014. 112 funds tracked by Wall St. Rank hold LUMO as of Q2 2016.

PointState Capital reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
PointState Capital sold 30,589 Lumos Pharma, Inc. Common Stock shares in Q2 2016, an estimated $5.01M.
PointState Capital first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
PointState Capital's Lumos Pharma, Inc. Common Stock position peaked at $29.7M in Q1 2014.
112 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2016.

Based on PointState Capital's 13F filing for Q2 2016, filed 15 Aug 2016.